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Background. In the context of hematopoietic stem cell transplantation (HSCT), mesenchymal stem cells (MSC) have
been used to promote engraftment and prevent graft-versus-host disease. However, in animal models, MSC were
shown to cause pulmonary alterations after systemic administration. The impact of MSC infusion on lung function
has not been studied in humans. The objective of the study was to investigate the impact of MSC co-infusion on lung
function and airway inflammation as well as on the incidence of pulmonary infections and cytomegalovirus (CMV)
reactivation after HSCT.
Methods. We have prospectively followed 30 patients who underwent unrelated HSCT with MSC co-infusion after
non-myeloablative conditioning (NMA). Each patient underwent detailed lung function testing (FEV1, FVC, FEV1/
FVC, RV, TLC, DLCO, and KCO) and measurement of exhaled nitric oxide before HSCT and 3, 6, and 12 months
posttransplant. The incidence of pulmonary infections and CMV reactivation were also monitored. This group was com-
pared with another group of 28 patients who underwent the same type of transplantation but without MSC co-infusion.
Results. Lung function tests did not show important modifications over time and did not differ between the MSC and
control groups. There was a higher 1-year incidence of infection, particularly of fungal infections, in patients having
received aMSC co-infusion. There was no difference between groups regarding the 1-year incidence of CMVreactivation.
Conclusions. MSC co-infusion does not induce pulmonary deterioration 1 year after HSCTwith NMA conditioning.
MSC appear to be safe for the lung, but close monitoring of pulmonary infections remains essential.
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Mesenchymal stem cells (MSC) are pluripotent cells de-rived from the bone marrow or other sources, which
have stimulated a high level of enthusiasm in recent years for
their potential therapeutic use.
In the context of allogeneic hematopoietic stem cell
transplantation (HSCT), MSC cotransplantation appears to
be safe (1, 2). These cells could have a role in engraftment
promotion (3) and graft-versus-host disease (GVHD) pre-
vention (4) through their immunosuppressive activity. Because
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of their lack of major histocompatibility complex molecule ex-
pression, MSC are weakly immunogenic in humans, allowing
administration to patients without HLA matching (5).
However, in some animal models, MSC infusion has
been shown to cause pulmonary alterations. Indeed, after
IV injection in mice, the cells are trapped within the pul-
monary capillaries, thereby causing embolism (6). Moreover,
mouse MSC could differentiate into tumor cells in lungs after
systemic administration (7) and could promote tumor de-
velopment (8). Another study in mice disclosed differentia-
tion of MSC in the lung after irradiation, depending on
the infusion timing (9): MSC differentiated into functional
lung cells if injected at an early stage or into cells involved in
fibrosis if injected once chronic inflammation and fibrosis
had started. Furthermore, Salazar et al. showed evidence of a
mitogenic potential of human and mouse MSC on lung fi-
broblasts in vitro (10). In contrast, other papers have shown
that, in response to injury caused by endotoxin or bleomycin,
MSC migrated to the lung, decreased tissue damage, and im-
proved lung repair (11, 12). In addition, in rats with chronic
obstructive lung disease, intra-tracheal MSC administration
restored lung function (13). These observations may result
from the ability of MSC to secrete paracrine growth factors
and cytokines able to decrease inflammation. Moreover, the
ability of MSC to differentiate into functional cells may be a
key in promoting adequate lung repair. MSC are also sug-
gested to be able to attenuate oxidative stress in inflammatory
lung diseases induced by previous irradiation or by subclinical
pathogen colonization in a context of immunosuppression (14).
The impact on the lung of MSC co-infusion after HSCT
has not been studied so far in humans. In this study, we
monitored the evolution of lung function, the value of ex-
haled nitric oxide (FeNO), and the occurrence of pulmonary
infections and cytomegalovirus (CMV) reactivation in pa-
tients who underwent HSCTwith MSC co-infusion. We also
investigated the impact of MSC co-infusion on CMV reac-
tivation and pulmonary infections in univariate and multi-
variate Cox models adjusted for competing risks.
It is widely accepted that performing pulmonary func-
tion tests (PFT) before and after transplantation is crucial to
detect early signs of pulmonary complications. Lung function
assessment before transplantation usually serves as baseline
reference to evaluate changes after HSCT (15). We followed
30 patients who received HSCT for hematological malignan-
cies from unrelated donors and a co-infusion of MSC after
non-myeloablative conditioning (NMA). The results were
compared with those of 28 patients who received the same
type of transplant but without MSC. Pulmonary function pa-
rameters, including airway flow rates, lung volumes, and dif-
fusing capacity (DLCO), as well as FeNO value, were measured
before HSCT as well as 3, 6, and 12 months posttransplan-
tation. FeNO is a noninvasive marker of airway inflammation
used to monitor rejection after lung transplantation (16), but
its utility has not been really assessed after HSCT.
RESULTS
At baseline, all patients displayed normal spirometric
and lung volume values but a slight impairment of diffusing
capacity. The median FeNO value was within the accepted
normal range for both patient groups (17).
MSC co-infusion had no detrimental effect on lung
function indices when expressed as predicted percentages
(see Table S1, SDC, http://links.lww.com/TP/A951). When ex-
pressed as absolute value (data not shown), MSC co-infusion
was even associated with a slight improvement in FEV1
(from 2.7T0.9 L at baseline to 2.9T0.9 L at 3 months, PG0.05)
and FVC (from 3.6T1.1 L at baseline to 3.8T1.1 at 6 months,
PG0.05) at some time points, which contrasted with the de-
crease in DLCO seen at 1 year in the group without MSC co-
infusion (from 6.3T1.8 at baseline to 5.8T1.1 at 1 year, PG0.05).
The other lung parameters (FEV1/FVC, KCO, TLC, RV,
and FeNO) were not significantly changed after 3, 6, or
12 months in any of the patient groups and did not show
differences between groups when expressed as predicted per-
centages or absolute values.
The 1-year cumulative incidence of pulmonary infec-
tion appeared higher in the MSC group compared to the
control group (PG0.01; see Table 1 and Figure S1A, SDC,
http://links.lww.com/TP/A951). Infection etiologies showed
a trend for a higher rate of fungal infections in the MSC
group (6 vs. 1; P=0.06). In contrast, the cumulative incidence of
CMV reactivation did not show any difference between groups
(see Figure S1B, SDC, http://links.lww.com/TP/A951). It should
be emphasized that patients in the MSC group were all
TABLE 1. Cumulative incidence of aGVHD, cGVHD, CMV reactivation, secondary neutropenia, and pulmonary infection
(including etiology)
MSC group n=30 Controls n=28 P
1-Yr cumulative incidence of grade IIYIV acute GVHD (%) 30 36 0.6
1-Yr cumulative incidence of chronic GVHD (%) 67 52 0.14
Moderate-severe GVHD (%) 46 33 0.3
1-Yr cumulative incidence of CMV reactivation (%) 40 43 0.76
1-Yr cumulative incidence of neutropenia (%) 14 4 0.17
1-Yr cumulative incidence of pulmonary infection (%) 48 15 0.0074
Unknown origin (n=) 9 3 0.12
Fungal (n=) 6 1 0.06
Viral (n=) 1 0 0.35
Bacterial (n=) 3 2 0.71
Total (n=) 19 6 0.02
GVHD, graft versus host disease; CMV, cytomegalovirus.
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HLA-mismatched while controls were 10/10 HLA-matched
at the allelic level.
In univariate Cox analysis of the whole cohort (n=58),
MSC co-infusion showed a significant association with the oc-
currence of pulmonary infections (HR=2.96 [1.15Y7.60], PG0.05)
whereas aspergillosis before HSCT and female donor-to-male
recipient were borderline significant (P=0.05 and P=0.08, re-
spectively, see Table S2, SDC, http://links.lww.com/TP/A951).
After multivariate analysis adjusting for aspergillosis before
HSCT, female donor-to-male recipient, andMSC co-infusion,
there was only a trend for an association between MSC and pul-
monary infections (P=0.09). The only significant risk factor
was aspergillosis before HSCT (HR: 3.19 [1.08Y9.43], PG0.05).
In univariate analysis, recipient (HR=7.78 [2.31Y26.3],
P=0.0009) and donor (HR=2.28 [1.03Y5.03], P=0.04) CMV
serostatus, but not MSC co-infusion, predicted for CMV
reactivation, whereas age (P=0.07) and female donor-to-male
recipient (P=0.09) were borderline significant. In multivariate
analysis, the only parameters that appeared significant were
the donor and recipient CMV positive status (HR=2.54
[1.10Y5.84], P=0.03 and HR=7.56 [2.18Y26.23], P=0.001, re-
spectively) and female donor-to-male recipient was borderline
significant (HR=2.25 [0.87Y5.81], P=0.09) (see Table S2, SDC,
http://links.lww.com/TP/A951).
DISCUSSION
In this study, we investigated the impact of MSC co-
infusion on several clinical and laboratory outcomes of
patients who underwent HSCT. To investigate the effect of
MSC on the lung, we focused our analysis on pulmonary func-
tion monitoring and pulmonary infections.
At 1 year, even if all patients in the MSC group and
none in the control group received a graft from HLA-
mismatched donors, we did not observe any difference
between groups for the incidence of acute GVHD (aGVHD).
Indeed, transplantation from HLA-mismatched donors is
known to give less favorable outcome because of a higher in-
cidence of GVHD. In addition, the higher proportion of the
female-to-male combination, usually associated with a higher
risk of chronic GVHD (cGHVD) (18), was not correlated with
TABLE 2. Patient characteristics
MSC group n=30 Controls n=28 P
Age, yr 54T13 57T11 0.40
BMI 25T4 26T4 0.54
Gender (M/F) 21/9 12/16 0.04
Tobacco habits (n/ex/cs) 12/8/10 8/13/7 0.29
Comorbidities (HSCT-CI score) 2 (0Y9) 3 (0Y7) 0.16
Underlying malignancy









Disease risk (42): low/standard/high 7/17/6 7/16/5 0.98
No. cells transplanted (106/kg)
CD34+ cells 4.3 (1.0Y11.7) 6.1 (2.6Y14.5) 0.05
CD3+ cells 271 (92Y540) 320 (140Y598) 0.24
Patient/donor compatibility
10/10 HLA identical (allelic level) 0 28 G0.0001
Other 30 0
Female donor-to-male recipient 9 2 0.03
Other sex combinations 21 26
Aspergillosis before HSCT 5 3 0.51
CMV serologic status, recipient-donor




Results are expressed as meanTSD except for HCT-CI score and number of CD3+ and CD34+ cells transplanted expressed as median (range).
BMI, body mass index; n, non-smoker; ex, ex-smoker; cs, current smoker; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; CLL, chronic
lymphocytic leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; MPD, myeloproliferative
disorder; MM, multiple myeloma; PLL, prolymphocytic leukemia; HSCT, hematopoietic stem cell transplantation; CMV, cytomegalovirus.
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a greater incidence of cGVHD in the MSC group. These obser-
vations might attest for a protective effect of MSC against
GVHD, but this remains to be studied in prospective ran-
domized trials.
The original finding of our study is the fact that pa-
tients receiving MSC exhibited no deterioration in lung func-
tion indices over the first year of observation. There was even
a slight improvement in airway flow rates and vital capacity
and no change in lung diffusing capacity in the MSC group,
whereas the group without MSC exhibited a significant de-
crease in diffusion lung capacity reaching on average 10%
after 1 year. Although some animal data drew attention to the
potential fibrotic effect of MSC (10), our observation attests
that infused MSC did not result in excessive airway or lung
remodeling that could potentially alter lung function.
By contrast, the incidence of pulmonary infections ap-
peared to be higher in the MSC group, which was also HLA-
mismatched, compared to the control group that was
HLA-matched. This observation could theoretically be linked
to the immunosuppressive effects of MSC, GVHD, or CMV
reactivation (19). However, GVHD and CMV reactivation
were not predictive of lung infections, neither in univariate
nor in multivariate analyses, but we have no detailed data on
immune reconstitution. Likewise, neutropenia, aspergillosis
before HSCT, and tobacco status, all recognized risk factors
for pulmonary infections, in general (20Y22) were evaluated,
but only a previous episode of aspergillosis before HSCTwas
significantly predictive. It should be emphasized that these
analyses did not investigate the impact of MSC alone but
also the combined effect of HLA mismatch and MSC co-
infusion, as the two factors were systematically associated.
HLA mismatching could have caused a higher incidence of
severe GHVD in the MSC group and hence a greater risk of
fungal infections (23). However, we did not observe any dif-
ference between the groups for the incidence of aGVHD and
cGVHD. Nevertheless, we cannot exclude that immune re-
constitution may have been relatively impaired or delayed in
the MSC group because patients were all HLA-mismatched
with their donors.
Although MSC have been shown to possess antimi-
crobial properties, this ability has been essentially observed
in vitro or in animal models and in ex vivo models of human
lung tissues (24). Moreover, this property was mainly de-
scribed against bacterial, viral, and parasitic infections (25Y27).
Interestingly, we encountered a higher incidence of fungal in-
fections in the MSC group. Although not statistically signifi-
cant, the impact of MSC could have been significant if we
did not have to exclude from the study two cases with asper-
gillosis because they could not undergo PFT. However,
patients receiving MSC were also HLA-mismatched with their
donors, which could also favor infection. Forslow et al. also
found an association between MSC co-infusion and pneumonia-
related death (28). The majority of patients had mold-related
pneumonia, but authors were not able to prove the relation
with MSC co-infusion because of low patient numbers in this
study. However, in a further paper, the use of MSC was asso-
ciated with a higher incidence of invasive fungal infections in
case of severe aGVHD (29), which is in line with our results.
Contrary to pulmonary infections, MSC co-infusion
did not have an impact on CMV reactivation, and this was
attested by the fact that the cumulative incidence of CMV
reactivation did not differ from the control group. A similar
finding was observed in a recent paper by Lucchini et al.
(30), which demonstrated that MSC did not interfere with
antiviral responses in vivo. The only parameters found to be
strongly predictive of CMV reactivation in this study were
donor and recipient CMV positive status, which are widely
recognized as risk factors for such reactivation (31).
In conclusion, the main finding of our study is the fact
that patients who underwent HSCT with MSC co-infusion
after NMA showed no deterioration of lung function over a
period of 1 year after transplantation. Nevertheless, longer
follow-up in larger groups of patients would be required to
formally exclude any lung toxicity of MSC, in particular in
relation with cGHVD. However, the pulmonary infection
rate (mainly the occurrence of fungal infections) appeared to
be increased. This indicates the need for prolonged antifungal
prophylaxis and close monitoring of pulmonary infections in
patients after HSCT and MSC cotransplantation.
MATERIALS AND METHODS
Subjects
Patients who underwent HSCT after NMA conditioning in the University
Hospital Center of Liege between December 2006 and December 2012 were
screened for the following inclusion criteria: (1) conditioning with total
body irradiation (TBI) 2 Gy and fludarabine, (2) immunosuppression with
mycophenolate mofetil (MMF) and tacrolimus, (3) transplantation with pe-
ripheral blood stem cells (PBSC), (4) unrelated donor, and (5) minimal
follow-up of 100 days. Thirty-eight patients met the inclusion criteria in the
MSC group. Among them, eight were excluded because they did not have lung
function assessment 3 months after HSCT. Indeed, three patients died before
day 100 (one died of graft rejection and sepsis, one of relapse, and one of
GVHD and sepsis associated with organ failure). The other five patients were
not able to perform lung function tests at day 100 (two had invasive lung as-
pergillosis, complicated by renal failure in one; two had a relapse associated
with severe encephalopathy in one; one had severe GVHD and organ failure).
Consequently, 30 patients remained eligible in the MSC group. They took
all part in one of two consecutive clinical trials investigating the safety and
efficacy of MSC co-infusion at time of HSCT from mismatched unrelated
donors after NMA conditioning (1). In the non-MSC group, 35 patients
also undergoing HSCT after NMA conditioning were included. However,
three died before 100 days (two of relapse, one of GVHD associated with
sepsis and organ failure), and four did not perform lung function tests because
of poor health status (two had a relapse combined with sepsis, one had severe
GVHD associated with organ failure, and one had GVHD combined with
encephalopathy). Therefore, 28 patients remained eligible in the control
group. Characteristics of the patients are presented in Table 2. All patients
included in the NMA MSC trial had HLA mismatches (one allele up to
two antigens), whereas all controls were 10/10 HLA-matched at allelic level.
MSC were cultured as described previously (1, 32). The conditioning
regimen consisted of fludarabine 90 mg/m2, followed by a single dose of
2 Gy TBI administered on day 0 before infusion of cells. MSC were infused
first, followed by PBSC infused at least 60 to 120 min later. MMF was ad-
ministered orally from day 0 through day 42 at the dose of 15 mg/kg
three times a day. Tacrolimus was given orally at the dose of 0.06 mg/kg
twice a day starting on day j3 until day 180 and then progressively tapered
to be definitely discontinued by day 365 in the absence of GVHD. The con-
ditioning regimen and postgrafting immunosuppression used were identical
in the MSC and the control groups.
The diagnosis and clinical grading of aGVHD were performed according
to standard criteria (33, 34). Diagnosis and grading of cGVHD were made
using the National Institute of Health consensus criteria (35).
All subjects gave written informed consent for participation as well as for
collection and analyses of posttransplant data. The MSC clinical trials were
approved by the Ethics Committee of the University of Liege.
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Pulmonary Function Assessment
At each time point, subjects underwent a global lung function assessment
using a body box plethysmography (Sensormedics, Vmax series 22; Viasyhealthcare,
Yorba Linda, CA) allowing to measure flow rates, lung volumes, and diffusion
capacity according to ATS/ERS standard criteria (36Y38). Spirometry (measure
of forced expiratory volume in 1 sec: FEV1 and forced vital capacity) was
performed before and after 400 Hg inhaled salbutamol metered dose inhaler
administered through a Volumatic. Diffusion for carbon monoxide (DLCO)
was measured by the single breath washout technique and corrected for the
hemoglobin content. FeNO was measured using a chemoluminescence ana-
lyzer (NIOX; Aerocrine, Stockholm, Sweden) at a flow rate of 50 mL/sec, in ac-
cordance with the recommendation of the ATS/ERS task force (39).
Pulmonary Infections and CMV Reactivation
Standard prophylaxis against infections was used (40), and disease evalua-
tion was routinely carried out on days 40, 100, 180, and 365. Pulmonary in-
fections were diagnosed based on respiratory symptoms, microbial analysis of
bronchoalveolar lavage, and chest radiography or CT scan, or both. Bronchitis
leading to hospitalization and pneumonia were recorded. The day of the
first CMV reactivation episode, defined as the first viral load greater than
1,000 copies/mL by PCR, was also recorded and positive patients were treated
preemptively with ganciclovir. Secondary neutropenia was defined as an epi-
sode of at least 2 weeks with absolute neutrophil count less than 500 cells/HL
occurring at least 1 month after HSCT.
Statistical Analysis
Categorical parameters were compared using the chi-square test. Com-
parisons between PFT values before and after HSCT were performed using
paired t tests or Wilcoxon matched-pair signed rank tests for the FeNO
values. Intergroup comparisons were made using unpaired t tests or Mann-
Whitney tests as appropriate. Cumulative incidences of aGVHD, cGHVD,
neutropenia, CMV reactivation, and pulmonary infection were calculated
as previously described (41), taking death as competing event. The impact
of MSC co-infusion (and correlatively of HLA mismatch because of the
linkage between the two characteristics) on CMV reactivation and pulmo-
nary infections was assessed in univariate and multivariate Cox models.
Factors analyzed in univariate analysis were as follows: patient age, gender,
tobacco habits, acute leukemia versus other diagnoses, number of CD34+
cells transplanted, aspergillosis before HSCT, secondary neutropenia, grade
IIYIV aGVHD, female donor-to-male recipient versus other sex combina-
tions, and MSC co-infusion. CMV reactivation was also assessed as risk
factor for pulmonary infection, and pulmonary infection and donor and
recipient CMV serostatus were evaluated as risk factors for CMV reactiva-
tion. Factors with a P value less than 0.10 were then introduced into multi-
variate analysis. Differences were considered statistically significant when a
two-sided P value was less than 0.05. Statistical analyses were carried out
with GraphPad Prism (GraphPad Software, San Diego, CA) and SAS version
9.3 (SAS Institute, Cary, NC).
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